These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 22338149

  • 1. [Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia].
    Sui T, Zhang L, Zhou ZP, Xue F, Ge J, Yang RC.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):583-6. PubMed ID: 22338149
    [Abstract] [Full Text] [Related]

  • 2. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [Abstract] [Full Text] [Related]

  • 3. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 4. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [Abstract] [Full Text] [Related]

  • 5. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.
    Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, Zhang W, Li M, Tang F, Zhang X, Zeng X, Zhao Y, Zhang F.
    Rheumatology (Oxford); 2011 Sep; 50(9):1640-4. PubMed ID: 21571767
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
    Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, Durand JM.
    Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166
    [Abstract] [Full Text] [Related]

  • 7. Low-dose rituximab in adult patients with primary immune thrombocytopenia.
    Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.
    Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023
    [Abstract] [Full Text] [Related]

  • 8. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 10. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, Flowers CR, Knapp M, Hart L, Patel-Donnelly D, Glenn M, Gregory SA, Holladay C, Zhang T, Boral AL.
    J Clin Oncol; 2009 Oct 20; 27(30):5023-30. PubMed ID: 19770386
    [Abstract] [Full Text] [Related]

  • 11. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y, IDEC-C2B8 Study Group.
    Cancer Sci; 2011 Sep 20; 102(9):1698-705. PubMed ID: 21645173
    [Abstract] [Full Text] [Related]

  • 12. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.
    Am J Hematol; 2012 Mar 20; 87(3):321-3. PubMed ID: 22190262
    [Abstract] [Full Text] [Related]

  • 13. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C, Reu FJ, Ho AD, Hensel M.
    Ann Hematol; 2007 Oct 20; 86(10):711-7. PubMed ID: 17622529
    [Abstract] [Full Text] [Related]

  • 14. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
    Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S.
    Pediatr Blood Cancer; 2008 Apr 20; 50(4):822-5. PubMed ID: 17570702
    [Abstract] [Full Text] [Related]

  • 15. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T.
    Eur J Haematol; 2011 Feb 20; 86(2):117-23. PubMed ID: 21070370
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.
    J Clin Oncol; 2011 Sep 01; 29(25):3389-95. PubMed ID: 21810687
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ, Wang FH, Huang HQ, Luo HY, Li YH, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):490-4. PubMed ID: 16613687
    [Abstract] [Full Text] [Related]

  • 18. [Effect of different therapeutic regimens on regulatory T cells in patients of primary immune thrombocytopenia].
    Li ZY, Li DP, Yan ZL, Xing WW, Liu KG, Cao J, He XP, Pan XY, Xu KL.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun 01; 34(6):478-81. PubMed ID: 23827100
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients.
    Kim JH, Kim YH, Kim MR, Kim SC.
    Br J Dermatol; 2011 Sep 01; 165(3):646-51. PubMed ID: 21574976
    [Abstract] [Full Text] [Related]

  • 20. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network.
    J Clin Oncol; 2003 May 01; 21(9):1746-51. PubMed ID: 12721250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.